BMY•benzinga•
Morgan Stanley Maintains Underweight on Bristol-Myers Squibb, Lowers Price Target to $63
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 2, 2022 by benzinga